mediators released from resident cells in the airways or from infiltrating inflammatory cells.
Glucocorticoids remain one of the most effective antiingoblet cell metaplasia flammatory agents available in treatment of asthma. The Bronchial asthma is a disease that is characterized by chronic inhibitory effect of glucocorticoids on synthesis of inflammainflammation, eosinophilic infiltration, reversible airway nartory mediators is considered the central mechanism of their rowing, airway hyperresponsiveness (AHR) to nonspecific efficacy. Glucocorticoids downregulate eotaxin in human airstimuli, hyperplasia/metaplasia of goblet cells, and subepiway mucosa (20) and IL-13-induced eotaxin expression in thelial fibrosis (1, 2) . Although the mechanisms underlying epithelial cells (21, 22) , but their inhibitory effects on the these features are complex, CD4 ϩ Th2 lymphocytes and their IL-13-dependent features are unknown. We studied the effects cytokine products, such as interleukin (IL)-4, IL-5, IL-9, and of dexamethasone on eosinophil accumulation, goblet cell IL-13, play a crucial role in generating these abnormalities.
hyperplasia, and AHR after IL-13 administration to the airIn patients with asthma, CD4 ϩ T cells producing IL-4, IL-5, ways. We also analyzed MUC5AC gene expression, a marker and IL-13 have been identified in bronchoalveolar lavage of goblet cell hyperplasia, in a murine model of allergic (BAL) and airway biopsy (3) . Animal studies have also asthma (23). The numbers of apoptotic cells in lung tissues shown that Th2 cells induced airway eosinophilia, mucus and in cells obtained by BAL were analyzed using terminal hypersecretion, and AHR (4, 5) .
deoxynucleotidyl transferase-mediated biotin nick end-labelIncreased expression of IL-13 has been demonstrated in ing (TUNEL) to assess whether dexamethasone may effect the airways of patients with asthma (6, 7) . Furthermore, local apoptosis of eosinophils. The proinflammatory cytokine tumor necrosis factor-␣ (TNF-␣) also causes AHR in rats and in humans (24, 25) , and it stimulates eotaxin expression in airway epithelial and smooth muscle cells in vitro (26-28).
(Received in original form October 23, 2001 ; accepted in final form August 22, 2002) Synergistic effects of IL-13 and TNF-␣ have been shown for induction of vascular cell adhesion molecule-1 (VCAM-1) in To examine the interaction between IL-13 and TNF-␣, the highthe first instillation of IL-13 and on 4 consecutive days (Day 0 to Day est dose of TNF-␣ that did not affect airway responsiveness 5, total 6 consecutive days). To examine the interaction between IL-13 (subthreshold dose) was determined. TNF-␣ (0.1, 1.0, and 10 and TNF-␣, the highest dose of TNF-␣ that did not affect airway responng; on Days 1, 3, and 5) was administered by instillation, and siveness (subthreshold dose) was used in combination with IL-13. airway responsiveness to inhaled acetylcholine was measured Measurements of airway responsiveness, BAL, histologic assesson Day 6. Intratracheal administration of 10 ng of TNF-␣ signifiment, and total RNA extraction from lung tissues were performed on cantly decreased PC 200 values in comparison to control values Day 6, 24 hours after the last instillation.
( Figure 1A) . A subthreshold dose of 1.0 ng of TNF-␣ did not affect airway responsiveness or eosinophil counts in BAL fluid
Measurement of Airway Responsiveness
( Figures 1A and 1C) . Therefore, we used 1.0 ng of TNF-␣ to Animals were anesthetized with a mixture of ketamine and sodium examine its interaction with IL-13. numbers of macrophages, neutrophils, and lymphocytes in BAL fluid in comparison to that with IL-13 alone (data not shown).
Histologic Assessment
There were no significant differences in baseline values of airway Lungs were fixed in 10% formalin, and tissue sections were stained with pressure between treatments. We conclude that the subthreshold Alcian blue/periodic acid-Schiff to determine the presence of mucin dose of TNF-␣ synergistically enhanced IL-13-induced eosinoglucoconjugates. TUNEL was performed using a commercial kit (Taphilia but not AHR. kara Biomedicals, Komatsu, Japan). The number of TUNEL-positive cells in the entire area of the section was counted under the microscope.
Effects of Dexamethasone on Eosinophils and Eotaxin in BAL Fluid and on AHR after IL-13 Determination of mRNA Expression of MUC5AC and
Instillation of IL-13 increased significantly the number of eosino- instillations. In mice receiving IL-13 instillations, there were in vivo. We also demonstrated that in IL-13-instilled animals, dexamethasone inhibits eotaxin expression and abolishes eosinoprominent Alcian blue/periodic acid-Schiff staining cells in the trachea, the main bronchi, and in the intrapulmonary bronchi phil accumulation but that it does not affect AHR, MUC5AC overexpression, or goblet cell hyperplasia. These findings suggest (Figure 4) . Treatment with dexamethasone did not affect inthat glucocorticoid is not sufficient to suppress IL-13-induced creases in Alcian blue/periodic acid-Schiff staining cells after AHR and goblet cell hyperplasia despite substantial inhibition IL-13 instillation. We also analyzed MUC5AC gene expression, of eosinophilic inflammation, at least partly through downregulaa marker of goblet cell hyperplasia (23). There was no difference tion of eotaxin expression. Eotaxin expression and eosinophilic in MUC5AC expression after vehicle instillation compared with inflammation have no causal relationship to the development of that in naive animals. IL-13 instillation markedly enhanced ex-AHR after airway administration of IL-13. pression of MUC5AC mRNA in the lung. Dexamethasone treat-
IL-13
The exact mechanism by which IL-13 induces AHR is unment did not affect overexpression of MUC5AC induced by known. L-4R␣ and IL-13R␣1 are expressed in airway epithelial IL-13 ( Figure 5 ). cells and smooth muscle cells (37, 38). IL-13 had an enhancing To assess whether dexamethasone may modulate expression effect on direct stimuli, such as acetylcholine or methacholine, of IL-13R, we examined mRNA expression of IL-13R␣1, ILalthough IL-13 itself did not constrict smooth muscle in vivo or 13R␣2, and soluble and membrane IL-4R. IL-13 instillation enin vitro (our unpublished observation). Therefore, IL-13 may hanced expression of IL-13R␣2 mRNA in the lung, but not exmodulate smooth muscle contractility either directly or indirectly pression of IL-13R␣1, soluble IL-4R, or membrane bound IL-4R.
through mediators released by surrounding cells other than eoThere were no detectable changes in the expressions of these sinophils. receptors with or without treatment with dexamethasone (Fig- Goblet cell hyperplasia and overexpression of MUC5AC ure 6).
after IL-13 administration were unaffected by dexamethasone even though dexamethasone markedly inhibited eosinophil ac-
DISCUSSION
cumulation. This finding is consistent with other work that has In this study, we demonstrated that TNF-␣ enhances eosinophil shown that airway epithelial mucus production can be induced by Th2 cells in the absence of eosinophils and that signaling infiltration in the airways but not AHR in IL-13-treated mice through IL-4R␣, a common receptor chain of IL-4R and ILexposure in vivo. The effect of glucocorticoid on MUC5AC 13R, is required to stimulate mucus production (39) . expression in human epithelial cells in vitro is controversial.
Glucocorticoid suppresses the expression of CC chemokines
Dexamethasone is reported to attenuate steady-state mRNA in epithelium by both transcriptional and post-transcriptional levels of MUC5AC (40), whereas it is reported to upregulate mechanisms (22) . In this study, dexamethasone inhibited eotaxin MUC5AC expression (41). The mechanisms by which IL-13-production and abolished eosinophil accumulation after IL-13 induced AHR, MUC5AC overexpression, and goblet cell hyperplasia resistant to glucocorticoid are not clear. The IL-13-induced asthma phenotypes are dependent on the IL-4R␣ chain and STAT6 in naive mice (8, 42) . Modification of receptor expression by dexamethasone does not seem to be responsible for steroid resistance because IL-13R␣1, IL-13R␣2, and IL-4R expression were not affected by dexamethasone in this study.
Although it is possible that apoptotic eosinophils induce AHR after glucocorticoid treatment, dexamethasone did not increase affinity in monocytes (43) . This may contribute to the impaired effect of glucocorticoids on IL-13-induced AHR in our experiment. It is suggested that the relative amount of glucocorticoid receptor expressed within a cell determines the magnitude and nature of the response to glucocorticoids (44). The relative ratio of glucocorticoid receptor to other transcription factors within tory cytokines such as IL-13 but not through modulating the actions of overexpressed IL-13. a given cell type determines whether the predominant consequence will be transcription enhancement or repression for cerSubthreshold TNF-␣ did not stimulate eosinophil accumulation by itself, whereas it augmented eosinophilic inflammation tain target genes (45) . Furthermore, although IL-13R subunit expressions in the whole lung were not affected by glucocorticoid induced by IL-13, consistent with an earlier report on IL-13-in this study, it is possible that glucocorticoid differentially reguinduced eotaxin expression (31) . In contrast to this synergistic lates the expression of IL-13R subunit in each cell type.
effect on eosinophilia, TNF-␣ did not enhance IL-13-induced In contrast to our expectation, treatment with dexamethasone AHR. These findings are supported by observations that eotaxin did not inhibit AHR induced by exogenous IL-13. AHR is supinstillation alone does not induce AHR despite the presence of posed to be linked to the inflammatory processes in the airways eosinophils in the airways and that additional factors such as of patients with asthma (46) . Dexamethasone suppresses aller-IL-5 or platelet activating factor (PAF) are needed to activate gen-induced airway eosinophilia and AHR in animals (47, 48).
eosinophils for the development of AHR (32, 51) . It has been reported that IL-13 induces eotaxin expression in This study has provided an important clue for further research epithelial cells in vitro (21, 22) and in the lung in vivo (31) and that glucocorticoid downregulates eotaxin expression induced by IL-13 in vitro (21); however, to the best of our knowledge, there is no report regarding the effect of glucocorticoids on IL-13-induced AHR. Glucocorticoids suppress expression and production of IL-13 by mast cells in vitro (49) , and antigeninduced gene expression of IL-13 in peripheral blood mononuclear cells is downregulated by dexamethasone (50) . Therefore, we speculate that glucocorticoids inhibit allergen-induced airway eosinophilia and AHR through downregulating proinflamma- 
